INCLUSION CRITERIA |
| Patients with a clinical diagnosis of Steroid-Dependent Vernal Keratoconjunctivitis
(Steroid-Dependent VKC: VKC Patients whose signs and symptoms only responded to topical corticosteroids and not to other medications). |
| Patients of either gender, 5 years or older. |
EXCLUSION CRITERIA |
| Patients with one blind eye. |
| Patients with visual acuity of 20/40 or worst in any of both eyes without a justifying cause. |
| Patients who are in an active stage of any other ocular inflammatory disease besides of VKC. |
| Patients receiving medication through topical ocular route of administration or any other that can in a very determinant way interfere in the results of the study, up to 48 hours prior to day 1 of study or until a period of time in which there are still residual effects. Such medication as systemic NSAIDs, systemic steroidal anti inflammatory drugs, systemic immunosuppressants and ocular topical lubricants. |
| Patients with history of hypersensitivity or any medical situation that contraindicates or makes risky the use of any of the study articles or their compounds under any route of administration as well as any drug or formulation derived from them or related to them. |
Contact lenses users. |
| Patients enrolled in any medical trial out of Laboratorios Sophia, S.A. de C.V. sponsorship under the last 90 days prior to this trial. |
| Patients who cannot comply with the medical appointments or with all the protocol requirements. |
| Patients who disagree to participate in this clinical trial. |
